Barriers and Facilitators to Oral PrEP Use Among Transgender Women in New York City
- PMID: 29589137
- PMCID: PMC6160363
- DOI: 10.1007/s10461-018-2102-9
Barriers and Facilitators to Oral PrEP Use Among Transgender Women in New York City
Abstract
Transgender women may face a disparate risk for HIV/AIDS compared to other groups. In 2012, Truvada was approved for daily use as HIV pre-exposure prophylaxis (PrEP). However, there is a dearth of research about barriers and facilitators to PrEP in transgender women. This paper will shed light on transgender women living in New York City's perceived and actual challenges to using PrEP and potential strategies to overcome them. After completing an initial screening process, four 90-min focus groups were completed with n = 18 transgender women. Participants were asked what they like and dislike about PrEP. Participants identified the following barriers: uncomfortable side effects, difficulty taking pills, stigma, exclusion of transgender women in advertising, and lack of research on transgender women and PrEP. Facilitators included: reducing pill size, increasing the types of available HIV prevention products, and conducting scientific studies to evaluate PrEP in transgender women.
Keywords: Barriers; Facilitators; HIV prevention; PrEP; Transgender women; Transwomen.
Conflict of interest statement
All authors declare that they have no conflicts of interest.
Similar articles
-
Stigma and Conspiracy Beliefs Related to Pre-exposure Prophylaxis (PrEP) and Interest in Using PrEP Among Black and White Men and Transgender Women Who Have Sex with Men.AIDS Behav. 2017 May;21(5):1236-1246. doi: 10.1007/s10461-017-1690-0. AIDS Behav. 2017. PMID: 28108878 Free PMC article.
-
Acceptability of HIV Pre-Exposure Prophylaxis Among Transgender Women in India: A Qualitative Investigation.AIDS Patient Care STDS. 2020 Feb;34(2):92-98. doi: 10.1089/apc.2019.0237. Epub 2020 Jan 17. AIDS Patient Care STDS. 2020. PMID: 31951490 Free PMC article.
-
HPTN 083-02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP study.J Int AIDS Soc. 2024 May;27(5):e26252. doi: 10.1002/jia2.26252. J Int AIDS Soc. 2024. PMID: 38783534 Free PMC article.
-
Pharmacology and drug interactions with HIV PrEP in transgender persons receiving gender affirming hormone therapy.Expert Opin Drug Metab Toxicol. 2020 Jun;16(6):463-474. doi: 10.1080/17425255.2020.1752662. Epub 2020 Apr 21. Expert Opin Drug Metab Toxicol. 2020. PMID: 32250177 Review.
-
Barriers and facilitators to HIV pre-exposure prophylaxis for cisgender and transgender women in the UK.Lancet HIV. 2023 Jul;10(7):e472-e481. doi: 10.1016/S2352-3018(23)00080-2. Epub 2023 Jun 1. Lancet HIV. 2023. PMID: 37271160 Review.
Cited by
-
Correlates of PrEP Uptake Among Young Sexual Minority Men and Transgender Women in New York City: The Need to Reframe "Risk" Messaging and Normalize Preventative Health.AIDS Behav. 2021 Oct;25(10):3057-3073. doi: 10.1007/s10461-021-03254-4. Epub 2021 Apr 8. AIDS Behav. 2021. PMID: 33830327 Free PMC article.
-
Factors influencing pre-exposure prophylaxis uptake among current users: A qualitative study.J HIV AIDS Soc Serv. 2020;19(3):252-262. doi: 10.1080/15381501.2020.1810838. Epub 2020 Aug 27. J HIV AIDS Soc Serv. 2020. PMID: 34290572 Free PMC article.
-
The development of a conceptual framework on PrEP stigma among adolescent girls and young women in sub-Saharan Africa.J Int AIDS Soc. 2024 Feb;27(2):e26213. doi: 10.1002/jia2.26213. J Int AIDS Soc. 2024. PMID: 38379129 Free PMC article. Review.
-
Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial.Lancet HIV. 2023 Nov;10(11):e703-e712. doi: 10.1016/S2352-3018(23)00200-X. Epub 2023 Sep 29. Lancet HIV. 2023. PMID: 37783219 Free PMC article. Clinical Trial.
-
Barriers and Facilitators to PrEP Initiation and Adherence Among Transgender and Gender Non-Binary Individuals in Southern California.AIDS Educ Prev. 2020 Dec;32(6):472-485. doi: 10.1521/aeap.2020.32.6.472. AIDS Educ Prev. 2020. PMID: 33779208 Free PMC article.
References
-
- FDA approves first drug for reducing the risk of sexually acquired HIV infection. 2012. [press release]
-
- Baral SD, Poteat T, Stromdahl S, Wirtz AL, Guadamuz TE, Beyrer C. Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(3):214–22. - PubMed
MeSH terms
Substances
Grants and funding
- P30 MH43520/MH/NIMH NIH HHS/United States
- MAF CU13-3233/Mac AIDS Fund
- R01 HD079603/HD/NICHD NIH HHS/United States
- K01 MH115785/MH/NIMH NIH HHS/United States
- P30 MH043520/MH/NIMH NIH HHS/United States
- UM1 AI120184/AI/NIAID NIH HHS/United States
- P30 AI117943/AI/NIAID NIH HHS/United States
- P30 AI117943/AI/NIAID NIH HHS/United States
- T32 MH019139/MH/NIMH NIH HHS/United States
- UM1 AI120184/AI/NIAID NIH HHS/United States
- R01 HD079603/HD/NICHD NIH HHS/United States
- T32 MH019139/MH/NIMH NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous